[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Unidade Local de Saude do Nordeste\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100638533","plasma-exchange-half-dose-and-extracorporeal-detoxification-for-aclf-100638533",false,"NCT07593638","Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF","Phoenix","Inclusion Criteria:\n\n* Written informed consent for participation in the study\n* Admission to the ICU with a diagnosis of ACLF of reversible etiology (infection, bleeding, alcohol-related, toxic, etc.)\n* Total bilirubin ≥ 12 mg\u002FdL and INR ≥ 1.5\n* On the waiting list for liver transplantation or not a candidate for transplantation but with an indication for supportive therapy\n\nExclusion Criteria:\n\n* Refusal to provide consent\n* Pregnancy\n* Expected survival \\\u003C 24 hours due to disease severity (hemodynamic instability requiring norepinephrine \\> 0.20 mcg\u002Fkg\u002Fmin and\u002For mechanical ventilation with PaO₂\u002FFiO₂ \\\u003C 150 and\u002For non-hepatic coma)\n* ACLF severity greater than CLIF-C ACLF grade 3\n* Advanced organ dysfunction: Pulmonary (GOLD stage 3 or 4) and\u002For Cardiac (NYHA functional class III or IV)\n* Advanced or metastatic oncological disease (life expectancy \\\u003C 6 months)\n* Marked frailty syndrome or secondary sarcopenia\n* Participation in another clinical trial within the previous 3 months","ALL","18 Years",{"count":19,"type":20},240,"ESTIMATED","INTERVENTIONAL",[23],"NA","Clinical trial\n\nThe goal of this clinical trial is to learn if a liver support protocol works to treat Liver failure in adults. The main questions it aims to answer are:\n\n* Does hemoadsorption plus half-dose plasma exchange provide support to liver failure patients until recovery or transplant\n* What medical problems do participants have during the technique? Researchers will compare DPMAS plus half-dose plasma exchange with conventional treatment to evaluate a gain in recovery\n\nParticipants will:\n\n* Be submitted to DPMAS plus half dose plasma exchange daily according to protocol.\n* Monitoring will be continuous in the ICU",[26],"Acute on Chronic Liver Failure (ACLF)",[28,29,30],"DPMAS","Plasma exchange","ACLF","NOT_YET_RECRUITING","2026-05-11",{"date":34,"type":35},"2026-05-18","ACTUAL",{"date":37,"type":20},"2026-07",{"date":39,"type":20},"2028-01",{"name":41,"class":42},"Unidade Local de Saude do Nordeste","OTHER",""]